BMS seeks to invigorate its autoimmune pipeline with acquisition of Padlock
By Taskin Ahmed & Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 4 (Table of Contents)
Published: 15 Apr-2016
DOI: 10.3833/pdr.v2016.i4.2153 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its autoimmune pipeline, Bristol-Myers Squibb (BMS) entered into an agreement to acquire the biotechnology startup firm Padlock Therapeutics which specializes in development of drugs that inhibit Protein/Peptidyl Arginine Deiminase (PAD) enzymes to treat autoimmune disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Login Problems
RSS